Published in Vaccine Weekly, March 10th, 1997
"These vectors should be taken into consideration in the design of vaccines and also as a means to stimulate specific T-cell responses in chronic HCV carriers," Oscar Bruna-Romero and colleagues wrote ("Induction of Cytotoxic T-Cell Response Against HCV Structural Antigens Using a Defective Recombinant Adenovirus," Hepatology, February 1997;25(2):470-477).
HCV infection has a strong tendency to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.